Warning: Javascript must be enabled within your browser's settings for this site to function properly.

Your browser appears to be out of date, and is not supported by this site. For the best experience, we recommend that you upgrade to a more modern browser. You can find a list of modern browsers from www.browsehappy.com.

We use technical and analytics cookies data to ensure that we give you the best experience on our website. For more information visit our Privacy Page.

BWXT $   $  
As of . Minimum 20 minute delay.

News

BWX Technologies Reports Fourth Quarter and Full Year 2023 Results, Initiates 2024 Guidance

27 February 2024

BWX Technologies, Inc. (NYSE: BWXT) reported fourth quarter and full year 2023 results.


BWXT Subsidiary Awarded $122 Million Contract Extension for Uranium Downblending Services

14 February 2024

(LYNCHBURG, Va. – February 14, 2024) – BWX Technologies, Inc. (NYSE: BWXT) today announced that its Nuclear Fuel Services, Inc. (NFS) subsidiary was awarded a $122 million contract extension from the Tennessee Valley Authority (TVA) for the downblending of highly enriched uranium (HEU) into low enriched uranium (LEU).


BWX Technologies to Announce Fourth Quarter and Full-Year 2023 Results on Tuesday, February 27

18 January 2024

BWX Technologies, Inc. (NYSE: BWXT) will issue a press release detailing fourth quarter and full-year 2023 results on Tuesday, February 27, 2024 after market close and will host a conference call at 5:00 p.m. EST.


BWXT Names Nicole W. Piasecki to Board of Directors

03 January 2024

(LYNCHBURG, Va. – January 3, 2024) – BWX Technologies, Inc. (NYSE: BWXT) announced today that Nicole W. Piasecki has been appointed to its board of directors effective January 2, 2024.


BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology

16 November 2023

(OTTAWA, Ontario – November 16, 2023) – BWXT Medical Ltd. and Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced that the companies have entered into an agreement for the supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials.


BWXT Names Mike Boorstein as New General Manager for Euclid Manufacturing Facility

09 November 2023

(EUCLID, Ohio – November 9, 2023) – BWX Technologies, Inc. (NYSE: BWXT) has appointed Mike Boorstein as the new general manager for its Nuclear Operations Group-Euclid manufacturing facility.


BWXT Selected as Nuclear Fuel and Component Manufacturer for Air Force Research Laboratory’s JETSON Program

08 November 2023

BWX Technologies, Inc. announced that it has been selected as the nuclear fuel and components manufacturer for the Air Force Research Laboratory’s Joint Emergent Technology Supplying On-Orbit Nuclear (JETSON) high power mission application program



BWXT Announces $300 Million Contract for Naval Nuclear Reactor Fuel

24 October 2023

BWX Technologies, Inc. announced the award of a U.S. Naval Nuclear Propulsion Program contract totaling approximately $300 million for the manufacture of naval nuclear reactor fuel.


BWXT, Crowley Debut Nuclear Power Generation Vessel Concept

20 September 2023

(LYNCHBURG, Va. – September 20, 2023) – Global shipping and energy supply chain leader Crowley has teamed with BWX Technologies, Inc. (NYSE: BWXT) through a memorandum of understanding for a ship concept that has the potential to generate alternative, zero-carbon emission energy for defense and disaster needs by including a microreactor on board.

Press Contacts:

BWX Technologies, Inc.

Jud Simmons 
+1 434.522.3800
hjsimmons@bwxt.com

BWXT Canada Ltd.
BWXT Nuclear Energy Canada Inc.
BWXT Medical Ltd.

Monifa Miller
+1 519.242.8071
mamiller@bwxt.com 

Nuclear Fuel Services, Inc.

Laura Bailey 
+1 423.743.9141
lebailey@nuclearfuelservices.com 

Archive

Tags